Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases

Atherosclerosis

Volumn 143, Issue 1, 1999, Pages 163-170

  Tsai, Michael Y ^a   Welge, Barry G ^b   Hanson, Naomi Q ^a   Bignell, Michelle K ^a   Vessey, John ^a   Schwichtenberg, Kerry ^a   Yang, Feng ^a   Bullemer, Faye E ^b   Rasmussen, Rhonda ^b   Graham, Kevin J ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

B vitamins; Cardiovascular diseases; Cystathionine synthase; Homocysteine; Methionine load; Methionine synthase; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DNA; HOMOCYSTEINE; METHIONINE; METHIONINE SYNTHASE; VITAMIN B GROUP;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; AGE OF ONSET; CORONARY DISEASE; CYSTATHIONINE BETA-SYNTHASE; FASTING; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHIONINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; POLYMORPHISM, GENETIC;

EID: 20244366362     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00271-8     Document Type: Article

References (34)

1. Selhub J., Jacques P.F., Bostom A.G., Agostino R.B., Wilson P.W.F., Belanger A.J., O'Leary D.H., Wolf P.A., Schaefer E.J., Rosenberg I.H. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N. Engl. J. Med. 332:1995;286.
2. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattstropm L.E., Ueland P.M., Palma-Reis R.J. Plasma homocysteine as a risk factor for vascular disease. The European concerted action plan. J. Am. Med. Assoc. 277:1997;1775.
3. Stampfer M.J., Malinow M.R., Willet W.C., Newcomer L.M., Upson B., Ullman D., Tishler P.V. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. J. Am. Med. Assoc. 268:1992;877.
4. Arnesen E., Refsum H., Bonaa K.H., Ueland P.M., Forde O.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int. J. Epidemiol. 24:1995;704.
5. Perry I.I., Refsum H., Morris R.W., Ebrahim S.B., Ueland P.M., Shaper A.G. Prospective study of serum homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346:1995;1395.
6. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337:1997;230.
7. Boers G.H.J., Smals A.G.H., Trijbels F.J.M., Fowler B., Bakkeren J.A.J.M., Schoonderwaldt H.C., Kleijer W.J., Kloppenborg P.W.C. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N. Engl. J. Med. 313:1985;709.
8. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324:1991;1149.
9. Tsai M.Y., Garg U., Key N.S., Hanson N.Q., Suh A., Schwichtenberg K. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis. 122:1996;69.
10. Bostom A.G., Selhub J., Jacques P.F., Nadeau M.R., Williams R.R., Ellison R.C. Methionine intolerance with normal fasting total plasma homocysteine: initial results from the NHLBI family heart study. Irish. J. Med. Sci. 164s:1995;3.
11. Selhub J., Jacques P.F., Wilson P.W.F., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in the elderly. J. Am. Med. Assoc. 270:1993;2693.
12. Bostom A.G., Bianchi L., Tsai M.Y., Jacques P.F., Nadeau M.R., Rosenberg I.H. Excess prevalence of fasting and post-methionine loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler. Thromb. Vasc. Biol. 17:1997;1894.
13. Kozich V., Kraus E., de Franchis R., Fowler B., Boers G.H., Graham I., Karus J.P. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine β-synthase alleles at the molecular level. Hum. Mol. Genet. 4:1995;623.
14. Kluitjmans L.A., van den Heuvel L.P.W.J., Boers G.H.J., Frosst P., Stevens E., van Oost B.A., den Heijer M., Trijbels F.J.M., Rozen R., Blom H.J. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am. J. Hum. Genet. 58:1996;35.
15. Kang S.S., Wong P., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am. J. Hum. Genet. 48:1991;536.
16. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J.H., den Heijer M., Kluitjtmans L.A.J., van den Huevel L.P., Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature. Genet. 10:1995;111.
17. Ma J., Stampfer M.J., Hennekens C.H., Frosst P., Selhub J., Horsford J., Malinow R., Willett W., Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in the US physicians. Circulation. 94:1996;2410.
18. van Bockxmeer F.M., Mamotte C.D.S., Vasikaran S.D., Taylor R.R. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 95:1997;21.
19. Brugada R., Marian A.J. A common mutation in methylenetetra-hydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 128:1997;107.
20. Christensen B., Frosst P., Lussier-Cacan S., Selhub J., Goyette P., Rosenblatt D.S., Genest J., Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;569.
21. Verhoef P., Kok F.J., Kluijtmans L.A.J., Blom H.J., Refsum H., Ueland P.M., Kruyssen D.A.C.M. The 677 C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis. 132:1997;105.
22. Leclerc D., Campeau E., Goyette P., Adjalla C.E., Christensen B., Ross M., Eydoux P., Rosenblatt D.S., Rozen R., Gravel R.A. Human methionine synthase: cDNA cloning and identifications of mutations in patients of the cblG completion group of folate/cobalamin disorders. Hum. Mol. Genet. 12:1996;1867.
23. Li Y.N., Gulati S., Baker P.J., Brody L.C., Banerjee R., Kruger W.E. Cloning, mapping, and RNA analysis of the human methionine synthase gene. Hum. Mol. Genet. 12:1996;1851.
24. Gulati S., Baker P., Li Y.N., Fowler B., Kruger W., Brody L.C., Banerjee R. Defects in human methionine synthase in cblG patients. Hum. Mol. Genet. 12:1996;1859.
25. Chen L.H., Liu M.-L., Hwang H.-Y., Chen L.-S., Korenberg J., Shane B. Human methionine synthase: cDNA cloning, gene location, and expression. J. Biol. Chem. 272:1997;3728.
26. Shih V.E., Fringer J.M., Mandell R., Kraus J.P., Berry G.T., Heidenreich R.A., Korson M.S., Levy H.L., Ramesh V. A missense mutation (I278T) in the cystathionine β-synthase gene prevalent in pyridoxine-responsive homocystinuria and associated with mild clinical phenotype. Am. J. Hum. Genet. 57:1995;34.
27. Gallagher P.M., Ward P., Tan S., Naughten E., Kraus J., Sellar G., McConnell D.J. High frequency (71%) of cystathionine β-synthase mutation G307S in Irish homocystineuria patients. Hum. Mutat. 5:1995;177.
28. Hu F.L., Gu Z., Kozich V., Kraus J.P., Ramesh V., Shih V.E. Molecular basis of cystathionine β-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. Hum. Mol. Genet. 2:1993;1857.
29. Brattstrom L., Israelsson B., Hultberg B. Plasma homocysteine and methionine tolerance in early-onset vascular disease. Haemostasis. 19(suppl 1):1989;35.
30. SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC:SAS Institute, 1990.
31. Folsom A.R., Nieto F.J., McGovern P.G., Tsai M.Y., Malinow M.R., Eckfeldt J.H., Hess D.L., Davis C.E. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the atherosclerosis risk in communities (ARIC) study. Circulation. 98:1998;204.
32. Engbersen A.M.T., Franken D.G., Boers G.H.J., Stevens E.M.B., Trijbels F.J.M., Blom H.J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am. J. Hum. Genet. 56:1995;142.
33. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg I.H., Selhub J., Rozen R. Relation between folate status, a common mutations in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7.
34. Reed T., Malinow M.R., Christian J.C., Upson B. Estimates of heritability for plasma homocysteine levels in aging adult male twins. Clin. Genet. 39:1991;425.